A Registry Study on HIV-related Lymphoma
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
AIDS Related Lymphoma|HIV Related Lymphoma
2-year overall survival (OS), OS measured from the date of diagnosis to last follow-up or to death from any cause., 2 years|2-year progression-free survival (PFS), PFS calculated from the date of diagnosis to the time of progression, relapse, or death., 2 years
Incidence of relapse (IR), Based on establised response criteria, e.g. Chesson et al. JCO 2014, 5 years|Non-relapse mortality (NRM), Deaths unrelated to lymphoma, 5 years|5-year overall survival (OS), OS measured from the date of diagnosis to last follow-up or to death from any cause., 5 years|5-year progression-free survival (PFS), PFS calculated from the date of diagnosis to the time of progression, relapse, or death., 5 years
To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.